Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
17.11
-7.57 (-30.67%)
At close: Oct 31, 2024, 4:00 PM
17.13
+0.02 (0.12%)
After-hours: Oct 31, 2024, 4:21 PM EDT
Anika Therapeutics Revenue
Anika Therapeutics had revenue of $38.75M in the quarter ending September 30, 2024, a decrease of -6.54%. This brings the company's revenue in the last twelve months to $164.17M, up 0.52% year-over-year. In the year 2023, Anika Therapeutics had annual revenue of $166.66M with 6.67% growth.
Revenue (ttm)
$164.17M
Revenue Growth
+0.52%
P/S Ratio
1.54
Revenue / Employee
$459,854
Employees
357
Market Cap
253.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 166.66M | 10.43M | 6.67% |
Dec 31, 2022 | 156.24M | 8.44M | 5.71% |
Dec 31, 2021 | 147.79M | 17.34M | 13.29% |
Dec 31, 2020 | 130.46M | 15.85M | 13.83% |
Dec 31, 2019 | 114.61M | 9.06M | 8.58% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Enhabit | 1.04B |
DocGo | 742.84M |
ZimVie | 453.38M |
Amylyx Pharmaceuticals | 298.76M |
Voyager Therapeutics | 143.77M |
MaxCyte | 45.44M |
Alpha Teknova | 34.94M |
ClearPoint Neuro | 28.07M |
ANIK News
- 8 hours ago - Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics - PRNewsWire
- 12 hours ago - Anika Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 12 hours ago - Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical - GlobeNewsWire
- 14 days ago - Anika Announces Third Quarter 2024 Results Conference Call Date - GlobeNewsWire
- 27 days ago - Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Anika Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Anika to Participate in the Sidoti Virtual Investor Conference - GlobeNewsWire